These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16678008)

  • 1. Oxidative stress, microvascular dysfunction, and scleroderma: an association with potential therapeutic implications, a commentary on "Postocclusive reactive hyperemia inversely correlates with urinary 15-F2t-isoprostane levels in systemic sclerosis".
    Chung CP; Avalos I; Stein CM
    Free Radic Biol Med; 2006 May; 40(10):1698-9. PubMed ID: 16678008
    [No Abstract]   [Full Text] [Related]  

  • 2. Postocclusive reactive hyperemia inversely correlates with urinary 15-F2t-isoprostane levels in systemic sclerosis.
    Cracowski JL; Kom GD; Salvat-Melis M; Renversez JC; McCord G; Boignard A; Carpentier PH; Schwedhelm E
    Free Radic Biol Med; 2006 May; 40(10):1732-7. PubMed ID: 16678012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal amplitude and kinetics of digital postocclusive reactive hyperemia in systemic sclerosis.
    Gaillard-Bigot F; Roustit M; Blaise S; Gabin M; Cracowski C; Seinturier C; Imbert B; Carpentier P; Cracowski JL
    Microvasc Res; 2014 Jul; 94():90-5. PubMed ID: 24990822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High DNA oxidative damage in systemic sclerosis.
    Avouac J; Borderie D; Ekindjian OG; Kahan A; Allanore Y
    J Rheumatol; 2010 Dec; 37(12):2540-7. PubMed ID: 20843906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis and clinical relevance of microcirculation disorders in progressive scleroderma].
    Brenke A; Brenke R; Loreck D
    Dermatol Monatsschr; 1990; 176(1):27-33. PubMed ID: 2311789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digital thermal hyperaemia impairment does not relate to skin fibrosis or macrovascular disease in systemic sclerosis.
    Salvat-Melis M; Carpentier PH; Minson CT; Boignard A; McCord GR; Paris A; Moreau-Gaudry A; Cracowski JL
    Rheumatology (Oxford); 2006 Dec; 45(12):1490-6. PubMed ID: 16705051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The vasculopathy of Raynaud's phenomenon and scleroderma.
    Flavahan NA; Flavahan S; Mitra S; Chotani MA
    Rheum Dis Clin North Am; 2003 May; 29(2):275-91, vi. PubMed ID: 12841295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal capillary patterns and systemic disease in scleroderma (progressive systemic sclerosis).
    Maricq HR; Spencer-Green G; Leroy EC
    Bibl Anat; 1975; 13():248-9. PubMed ID: 1231740
    [No Abstract]   [Full Text] [Related]  

  • 9. Impaired flow-mediated vasodilation in type 2 diabetes: lack of relation to microvascular dysfunction.
    Meyer MF; Lieps D; Schatz H; Pfohl M
    Microvasc Res; 2008 May; 76(1):61-5. PubMed ID: 18448131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodological issues in the assessment of skin microvascular endothelial function in humans.
    Cracowski JL; Minson CT; Salvat-Melis M; Halliwill JR
    Trends Pharmacol Sci; 2006 Sep; 27(9):503-8. PubMed ID: 16876881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating microangiopathy in systemic sclerosis: what have we learnt and what is left to discover?
    Cutolo M; Sulli A; Smith V
    Expert Rev Clin Immunol; 2011 Jul; 7(4):395-7. PubMed ID: 21790279
    [No Abstract]   [Full Text] [Related]  

  • 12. Maximum blood flow and microvascular regulatory responses in systemic sclerosis.
    Gunawardena H; Harris ND; Carmichael C; McHugh NJ
    Rheumatology (Oxford); 2007 Jul; 46(7):1079-82. PubMed ID: 17494087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic sclerosis--a microvascular disorder?
    Jayson MI
    J R Soc Med; 1983 Aug; 76(8):635-42. PubMed ID: 6350584
    [No Abstract]   [Full Text] [Related]  

  • 14. The micro-circulation in systemic sclerosis.
    Jayson MI
    Clin Exp Rheumatol; 1984; 2(1):85-91. PubMed ID: 6398169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis.
    Sunderkötter C; Riemekasten G
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii33-5. PubMed ID: 16987831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress.
    Iwata Y; Ogawa F; Komura K; Muroi E; Hara T; Shimizu K; Hasegawa M; Fujimoto M; Tomita Y; Sato S
    Rheumatology (Oxford); 2007 May; 46(5):790-5. PubMed ID: 17309887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Difficulty in detecting reperfusion injury increment in oxidative stress among patients with primary Raynaud's phenomenon and systemic sclerosis.
    Herrick AL; Rieley F; Braganza JM; Jayson MI
    J Rheumatol; 1995 Feb; 22(2):374-5. PubMed ID: 7738971
    [No Abstract]   [Full Text] [Related]  

  • 18. [Determination of muscle microcirculation in the extremities of normal subjects and patients with scleroderma using 133Xenon-clearance. 2. Study of patients with progressive scleroderma].
    Pönitzsch I; Wiemers U; Haustein UF; Schneider G
    Radiobiol Radiother (Berl); 1984; 25(2):349-53. PubMed ID: 6739777
    [No Abstract]   [Full Text] [Related]  

  • 19. Association among C-reactive protein, oxidative stress, and traditional risk factors in healthy Japanese subjects.
    Dohi Y; Takase H; Sato K; Ueda R
    Int J Cardiol; 2007 Jan; 115(1):63-6. PubMed ID: 16759717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Microcirculatory disorders in the skin in systemic scleroderma].
    Akhnazarova VD; Balabanova RM
    Ter Arkh; 1979; 51(6):77-81. PubMed ID: 473057
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.